Evidence from the literature indicates that high levels of both sPD-1 and sPD-L1 in the serum of ovarian cancer patients are associated with advanced disease stage and poor prognosis, specifically reduced overall survival, and progression-free survival, which partially correlates with our results [25]. Here, SPDL1 is linked to ovarian carcinoma.